MECP2 and breast cancer: In conclusion, linc‐ROR serves as an onco‐lncRNA in breast cancer and promotes breast cancer cell survival during rapamycin treatment by functioning as a ceRNA sponge for miR‐194‐3p, which targets MECP2.